Navigation Links
Sunitinib Benefit Explored in Poor-Prognosis Kidney Cancer
Date:7/16/2009

Treatment safe in advanced disease but more study is needed, experts say

THURSDAY, July 16 (HealthDay News) -- The oral cancer drug sunitinib (Sutent) has shown promising results in advanced kidney cancer patients who have a poor prognosis, new research says.

Previous clinical trials showed that sunitinib was effective in patients with advanced kidney cancer, and the drug has been approved worldwide as a first- and second-line treatment for these patients, according to background information with the study. However, little is known about the drug's activity in advanced kidney cancer patients with poor prognosis, such as those whose cancer has spread to the brain, those with poor performance status, and the elderly.

The new study, published online and in the August print issue of The Lancet Oncology, included 4,564 poor-prognosis patients in 52 countries who were divided into four subgroups, including those with brain metastases, poor performance status, non-clear-cell renal cell carcinoma, and patients aged 65 and older.

All of the patients received 50 milligrams of sunitinib once daily, repeated in six-week cycles (four weeks on treatment followed by two weeks off treatment). The researchers assessed tumor response, toxicity, and adverse events at regular intervals.

The study authors reported that the median progression-free survival was 10.9 months, and overall survival was 18.4 months, which was an improvement over previous findings. In the four subgroups, the response rates were: brain metastases, 12 percent; non-clear-renal cell carcinoma, 11 percent; poor performance status, 9 percent; and elderly, 17 percent; with an overall objective response rate of 17 percent.

Overall, the study found that the drug can be given safely and is well-tolerated in all four subgroups. Diarrhea (44 percent) and fatigue (37 percent) were the most common treatment-related adverse events, the study authors noted.

In an article accompanying the study, experts added that "the safety and efficacy of sunitinib in an older population are confirmed and evidence shows that age alone should not be a deterrent from attempting therapy."

But "patients with brain metastases, non-clear-cell histology, and poor performance status benefit less from sunitinib, despite good drug tolerance, suggesting the need for prospective studies in these subpopulations," wrote Dr. Joaquim Bellmunt of Hospital del Mar in Barcelona, Spain, and the Dana-Farber Cancer Institute and Harvard Medical School in Boston, and Dr. Toni K. Choueiri of Dana-Farber and Harvard.

"Thus, claiming sunitinib as a 'standard' in these subgroups remains controversial. An oncologist might not have access to such trials in practice, however, and based on available information the use of sunitinib may be justified in these subpopulations," they concluded.

More information

The U.S. National Cancer Institute has more about kidney cancer.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, July 15, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. In Colorado, Commercial Medical and Pharmacy Benefit Enrollment Down at State Level
2. Cancer Patients Benefit From Speed, Accuracy of RapidArc Radiotherapy Treatments
3. Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit
4. A Phase III Alzheimers Drug Increases Levels of Beta Amyloid in the Brain - But Still Provides Benefits
5. Regular moderate alcohol intake has cognitive benefits in older adults
6. Pinnacle Health Solutions Launches New Web Site, Making Affordable Health Care and Benefits Easy to Understand
7. Chief Medical Officer Joins Aon Consultings Health & Benefits Practice
8. First Annual Congressional Womens Softball Game to Benefit the Young Survival Coalition
9. Harvard Medical School Continues Education About Benefits of Probiotics
10. Omega-3s Benefit Heart Attack Survivors, Healthy Adults, Mothers and Infants
11. The Max Cure Foundation Announces Its First Charity Benefit: The Roar for a Cure Carnival to Be Held on Saturday, August 22, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sunitinib Benefit Explored in Poor-Prognosis Kidney Cancer
(Date:3/24/2017)... Sedona, Arizona (PRWEB) , ... March 24, 2017 ... ... Shamangelic Healing Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, ... Jorge Luis Delgado, June 9--24, 2017. This sacred and spiritual journey during ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... are now offering treatments for sleep apnea and TMJ at their office. TMJ, ... apnea , specifically the obstructive type, is increasingly being treated at dental offices ...
(Date:3/24/2017)... ... March 24, 2017 , ... Viewers who like to educate ... historical facts, cultural practices, goods, services, and societal issues tend to appreciate and love ... the popular practice of utilizing running events for causes around the world. ...
(Date:3/24/2017)... ... March 24, 2017 , ... Judy Buchanan, co-owner of ... Frederick, MD. Judy says, “I am passionate about sharing Reiki as a holistic, ... difficult and challenging time.” , A Certified Medical Reiki™ Master trained by Raven ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation ... and college Bible teacher residing in North Carolina with his wife, Anna Marie. He ... them with six grandchildren. David is also the author of “Shadow and Substance.” , ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... HAYWARD, Calif. , March 27, 2017  Impax ... Directors has appointed Paul M. Bisaro as ... of the Company,s Board, effective March 27, 2017. Mr. ... has served as Interim President and Chief Executive Officer ... years of generic and branded pharmaceutical experience, Mr. Bisaro, ...
(Date:3/27/2017)... March 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), ... inherited liver diseases in children, today reported financial ... ended December 31, 2016 and provided an update ... continued to make progress during the fourth quarter ... from our non-human primate safety study, and with our ...
(Date:3/27/2017)... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... across multiple therapeutic areas, today announced that Amit Munshi , ... corporate update at the 16th Annual Needham Healthcare Conference on ... place April 4-5, 2017 at the Westin New York Grand ... A live audio webcast of the presentation will ...
Breaking Medicine Technology: